Vital KSK Holdings, Inc. AI Stock Analysis
Want to see JP:3151 full AI Analyst Report?
Vital KSK Holdings, Inc. (3151) AI Stock Analysis
Vital KSK Holdings, Inc.
(TSE/TYO:3151)
Vital KSK Holdings scores a moderate 57, reflecting a tension between attractive valuation and underlying financial concerns. The strongest factor is valuation: a P/E of 11.1x and a 4.3% dividend yield offer compelling value and income. The balance sheet is solid with low leverage and growing equity. However, the score is weighed down significantly by highly volatile and frequently negative cash flows, which undermine confidence in the sustainability of reported earnings. Ultra-thin operating margins (~1.2-1.8%) provide minimal buffer against operational disruptions. Technicals are neutral-to-mildly positive, with the stock in a longer-term uptrend but lacking near-term momentum. The stock is best suited for value-oriented investors comfortable with the inherent risks of a thin-margin distribution business with inconsistent cash generation.
Vital KSK Holdings, Inc. (3151) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 67.07B
- Dividend Yield
- 5.05%
- Average Volume (3M)
- 98.48K
- Price to Earnings (P/E)
- 23.8
- Beta (1Y)
- 0.44
- Revenue Growth
- 2.74%
- EPS Growth
- -71.04%
- Country
- Japan
- Employees
- 3,871
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Vital KSK Holdings, Inc. Business Overview & Revenue Model
Company Description
Vital KSK Holdings, Inc. is a Japanese entity primarily involved in the wholesale distribution of pharmaceutical products. Its diverse wholesale operations also cover veterinary medications, agricultural chemicals and supplies, and various types of m...
Vital KSK Holdings, Inc. Financial Statement Overview
Summary
Steady revenue growth to ¥600B and a strong net income recovery from ¥1.2B to ¥7.3B are positives, but ultra-thin margins (~1.2% net, ~1.4-1.8% EBIT) leave minimal room for error. The balance sheet is a bright spot with significant deleveraging (debt-to-equity at 0.07) and growing equity, earning a solid 68. However, highly erratic cash flows — negative operating cash flow in three of five years and deeply negative free cash flow in FY2025 — are a major concern, dragging the cash flow score to 35. The disconnect between reported profits and cash generation raises questions about cash conversion quality. Blended across the three sub-scores (income 48, balance sheet 68, cash flow 35), the overall financial picture is below average.
Income Statement
48NeutralBalance Sheet
68PositiveCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 620.07B | 610.50B | 600.37B | 587.48B | 579.77B | 577.25B |
| Gross Profit | 50.09B | 49.58B | 49.22B | 48.30B | 44.96B | 43.98B |
| EBITDA | 7.32B | 8.08B | 14.56B | 12.16B | 11.56B | 10.87B |
| Net Income | 2.86B | 7.36B | 7.31B | 5.84B | 4.83B | 4.77B |
Balance Sheet | ||||||
| Total Assets | 329.42B | 320.57B | 299.43B | 317.26B | 297.32B | 313.03B |
| Cash, Cash Equivalents and Short-Term Investments | 21.02B | 22.95B | 23.10B | 34.71B | 19.03B | 26.97B |
| Total Debt | 8.74B | 6.78B | 7.70B | 10.15B | 10.87B | 12.59B |
| Total Liabilities | 212.53B | 201.86B | 192.12B | 211.31B | 197.15B | 212.99B |
| Stockholders Equity | 115.37B | 117.22B | 105.91B | 104.66B | 98.99B | 98.96B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.11B | -10.59B | 18.47B | -9.60B | 3.35B |
| Operating Cash Flow | 0 | 4.83B | -8.02B | 23.57B | -3.00B | 7.49B |
| Investing Cash Flow | 0 | -1.07B | 3.52B | -1.82B | -1.04B | -2.01B |
| Financing Cash Flow | 0 | -4.40B | -6.54B | -5.77B | -4.08B | -8.49B |
Vital KSK Holdings, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3151, the sentiment is Negative. The current price of 1407.00 is below the 20-day moving average (MA) of 1508.05, below the 50-day MA of 1540.85, and below the 200-day MA of 1483.81, indicating a bearish trend. The MACD of -38.52 indicates Positive momentum. The RSI at 37.91 is Neutral, neither overbought nor oversold. The STOCH value of 19.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3151.
Vital KSK Holdings, Inc. Peers Comparison
Overall Rating
JP:606273Outperform
JP:707164Neutral
JP:268962Neutral- JP:315157Neutral
JP:926556Neutral
JP:341752Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:6062 | 73Outperform | JPY 63.98B | 14.42 | ― | 2.19% | 5.50% | 45.42% |
| JP:7071 | 64Neutral | JPY 36.18B | 11.24 | ― | 1.10% | 6.17% | -33.01% |
| JP:2689 | 62Neutral | JPY 19.15B | 11.32 | ― | 4.29% | 2.20% | -31.67% |
| JP:3151 | 57Neutral | JPY 61.46B | 23.81 | ― | 5.05% | 2.74% | -71.04% |
| JP:9265 | 56Neutral | JPY 9.45B | 16.84 | ― | 2.88% | -0.41% | 2.32% |
| JP:3417 | 52Neutral | JPY 13.52B | 18.43 | ― | 2.96% | 2.87% | -73.55% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3151 | Vital KSK Holdings, Inc. | 1407.00 | 191.90 | 15.79% | |
| JP:2689 | OLBA HEALTHCARE HOLDINGS, Inc. | 1865.00 | -74.60 | -3.85% | |
| JP:3417 | Ohki Health Care Holdings, Inc. | 1012.00 | -385.29 | -27.57% | |
| JP:6062 | Charm Care Corporation | 1962.00 | 738.90 | 60.41% | |
| JP:7071 | Amvis Holdings.Inc. | 362.00 | -92.36 | -20.33% | |
| JP:9265 | YAMASHITA HEALTH CARE HOLDINGS, INC. | 3710.00 | 567.28 | 18.05% |
Vital KSK Holdings, Inc. Corporate Events
VITAL KSK Subsidiary Begins Phase 2 Ferric Maltol Trial in Japan
VITAL KSK Holdings operates in the healthcare and pharmaceutical industry through subsidiaries developing and commercializing specialty treatments, including ferric maltol for iron deficiency and pulmonary arterial hypertension. Its market focus incl...
Vital KSK Raises Sales Forecast but Cuts Profit Outlook
Vital KSK Holdings, a Japanese pharmaceutical wholesaler serving the domestic healthcare market, raised its fiscal 2027 net sales forecast to ¥627.0 billion from ¥620.0 billion, supported by higher sales of anticancer drugs and influenza vaccines. Ho...
Vital KSK Reports Sales Growth Amid Sharp Interim Profit Declines
Vital KSK Holdings, a Tokyo-listed company, reported consolidated revenue of ¥309.8 billion for the six months ended September 30, 2026, up 3.2% from a year earlier. Core operating profit fell 37.4% to ¥1.4 billion, while operating profit declined 63...
Vital KSK Holdings Repurchases 326,900 Shares in October
Vital KSK Holdings, Inc. is a Tokyo-based company listed on the Tokyo Stock Exchange Prime Market. The company repurchased 326,900 common shares for approximately ¥498.7 million between October 1 and October 31, 2026, through market purchases under d...
Vital KSK Holdings Advances Share Buyback Under Ongoing Capital Program
Vital KSK Holdings, Inc. has continued its capital efficiency strategy through an ongoing share repurchase program authorized by its board in May 2026, allowing the company to buy back up to 2 million shares or ¥4 billion in stock. The company is lis...
Vital KSK Advances Share Buyback, Retains Significant Repurchase Capacity
Vital KSK Holdings has continued its ongoing share buyback program, repurchasing 195,100 common shares for approximately ¥317 million between August 1 and August 31, 2026 through market purchases under discretionary investment management. This transa...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026